Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation.

@article{Springer2016PreclinicalDS,
  title={Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation.},
  author={Michael J Springer and Yawei Ni and Isaac Finger-Baker and Jordan P Ball and Jessica L Hahn and Ashley V. DiMarco and Dean J Kobs and Bobbi Horne and James D. Talton and Ronald R Cobb},
  journal={Vaccine},
  year={2016},
  volume={34 12},
  pages={
          1452-8
        }
}
Norovirus is the primary cause of viral gastroenteritis in humans with multiple genotypes currently circulating worldwide. The development of a successful norovirus vaccine is contingent on its ability to induce both systemic and mucosal antibody responses against a wide range of norovirus genotypes. Norovirus virus-like particles (VLPs) are known to elicit systemic and mucosal immune responses when delivered intranasally. Incorporation of these VLPs into an intranasal powder vaccine offers the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-5 OF 5 CITATIONS

Human Norovirus: Experimental Models of Infection

VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.

  • Journal of controlled release : official journal of the Controlled Release Society
  • 2018

Intranasal immunization with dry powder vaccines.

  • European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  • 2018
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Norovirus Disease in the United States

  • Emerging infectious diseases
  • 2013
VIEW 1 EXCERPT